NCT06393036

The Effect of OSA on Severity and Prognosis of Patients With IgAN

The Effect of Obstructive Sleep Apnea on Severity and Prognosis of Patients With IgA Nephropathy

• Status: Not Yet Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 200 (estimated)
• Sponsor: Peking University First Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study aims to investigate the influence of obstructive sleep apnea hypopnea syndrome (OSA) on the severity and prognosis of patients with IgA nephropathy (IgAN), and to evaluate the therapeutic effect of continuous positive airway pressure (CPAP) intervention in such patients. Although the study is designed as an observational cohort study, where patients self-selected whether to receive treatment rather than being assigned, there is still an intervention project, CPAP, present in the observational cohort. Through a cohort study design, scientific evidences are expected for clinical decision-making and optimize treatment strategies for patients with OSA and IgAN.

Conditions

• Obstructive Sleep Apnea
• IgA Nephropathy

Interventions

Type	Name	Description
DEVICE	Continuous Positive Airway Pressure	The intervention in this study involves the use of Continuous Positive Airway Pressure (CPAP) treatment. Although the study is designed as an observational cohort study, where patients self-selected whether to receive treatment rather than being assigned, there is still an intervention project, CPAP, present in the observational cohort. CPAP is a commonly used therapy for obstructive sleep apnea (OSA) and other sleep-related breathing disorders. The principle of CPAP treatment lies in maintaining a constant airway pressure during sleep to prevent the collapse of the upper airway and ensure unobstructed breathing. The patient wears a mask connected to a CPAP machine, which generates a steady stream of air to provide the necessary pressure.

Timeline

• Start date: 2024-07-15
• Primary completion: 2025-12-31
• Completion: 2026-06-30
• First posted: 2024-05-01
• Last updated: 2024-06-04

Regulatory

• FDA-regulated device study